Literature DB >> 20974639

Tumorigenicity of MCF-7 human breast cancer cells lacking the p38α mitogen-activated protein kinase.

Rhone A Mendoza1, Emily E Moody, Marlene I Enriquez, Sylvia M Mejia, Gudmundur Thordarson.   

Abstract

We have generated cell lines with significantly reduced expression of the p38 mitogen-activated protein kinase (p38 MAPK), Min-p38 MAPK cells, and used these cells to investigate p38 MAPK's role in tumorigenesis of breast cancer cells. MCF-7 cells were stably transfected with a plasmid producing small interfering RNA that inhibited the expression of p38 MAPK. Control cells were stably transfected with the same plasmid producing non-interfering RNA. The reduction in the p38 MAPK activity caused a significant increase in the expressions of estrogen receptor-α (ERα) and the progesterone receptor, but eliminated the expression of ERβ. Min-p38 MAPK cells showed an enhanced overall growth response to 17β-estradiol (E₂), whereas GH plus epidermal growth factor were largely ineffective growth stimulators in these cells compared to controls. Although the long-term net growth rate of the Min-p38 MAPK cells was increased in response to E₂, their proliferation rate was lower compared to controls in short-term cultures. However, the Min-p38 MAPK cells did show a significant decreased rate of apoptosis after E₂ treatment and a reduction in the basal phosphorylation of p53 tumor suppressor protein compared to controls. When the Min-p38 MAPK cells were xenografted into E₂-treated athymic nude mice, their tumorigenicity was enhanced compared to control cells. Increased tumorigenicity of Min-p38 MAPK cells was caused mainly by a decrease in the apoptosis rate indicating that the lack of the p38 MAPK caused an imbalance to increase the ERα:ERβ ratio and a reduction in the activity of the p53 tumor suppressor protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974639      PMCID: PMC3242445          DOI: 10.1677/JOE-10-0237

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  37 in total

Review 1.  The p38 signal transduction pathway: activation and function.

Authors:  K Ono; J Han
Journal:  Cell Signal       Date:  2000-01       Impact factor: 4.315

2.  MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha.

Authors:  Baoxue Ge; Hermann Gram; Franco Di Padova; Betty Huang; Liguo New; Richard J Ulevitch; Ying Luo; Jiahuai Han
Journal:  Science       Date:  2002-02-15       Impact factor: 47.728

3.  p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation.

Authors:  M Takekawa; M Adachi; A Nakahata; I Nakayama; F Itoh; H Tsukuda; Y Taya; K Imai
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

4.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.

Authors:  J M Hall; D P McDonnell
Journal:  Endocrinology       Date:  1999-12       Impact factor: 4.736

5.  Estrogen receptor beta acts as a dominant regulator of estrogen signaling.

Authors:  K Pettersson; F Delaunay; J A Gustafsson
Journal:  Oncogene       Date:  2000-10-12       Impact factor: 9.867

6.  Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation.

Authors:  D V Bulavin; S Saito; M C Hollander; K Sakaguchi; C W Anderson; E Appella; A J Fornace
Journal:  EMBO J       Date:  1999-12-01       Impact factor: 11.598

7.  Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression.

Authors:  Meng-Min Liu; Chris Albanese; Carol M Anderson; Kristin Hilty; Paul Webb; Rosalie M Uht; Richard H Price; Richard G Pestell; Peter J Kushner
Journal:  J Biol Chem       Date:  2002-05-01       Impact factor: 5.157

8.  Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.

Authors:  P Roger; M E Sahla; S Mäkelä; J A Gustafsson; P Baldet; H Rochefort
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

9.  A novel high-through-put assay for screening of pro-apoptotic drugs.

Authors:  Maria Hägg; Kenneth Bivén; Takayuki Ueno; Lars Rydlander; Peter Björklund; Klas G Wiman; Maria Shoshan; Stig Linder
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

10.  Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation.

Authors:  Heehyoung Lee; Wenlong Bai
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

View more
  4 in total

1.  Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.

Authors:  Ming-Tsung Lee; Shuk-Mei Ho; Pheruza Tarapore; Irving Chung; Yuet-Kin Leung
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

2.  T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway.

Authors:  Shengqing Li; Feng Zhu; Tatyana Zykova; Myoung Ok Kim; Yong Yeon Cho; Ann M Bode; Cong Peng; Weiya Ma; Andria Carper; Alyssa Langfald; Zigang Dong
Journal:  J Biol Chem       Date:  2011-06-29       Impact factor: 5.157

3.  Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor.

Authors:  Bram Blomme; Femke Heindryckx; Jean Marie Stassen; Anja Geerts; Isabelle Colle; Hans Van Vlierberghe
Journal:  Mol Cell Biochem       Date:  2012-09-24       Impact factor: 3.396

Review 4.  Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease.

Authors:  Kallirroi Voudouri; Aikaterini Berdiaki; Maria Tzardi; George N Tzanakakis; Dragana Nikitovic
Journal:  Anal Cell Pathol (Amst)       Date:  2015-07-15       Impact factor: 2.916

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.